This editorial that I spotted via LinkedIn may be of interest to HIFA and CHIFA members interested in cerebral palsy?
"New Cochrane Library Editorial calls for accelerated global implementation of antenatal magnesium sulphate to benefit preterm babies."
https://www.cochrane.org/news/inexpensive-drug-can-prevent-cerebral-pals...
[*see note below]
Best wishes
Julie
HIFA profile: Julie N Reza is a UK-based specialist in communications for biosciences, global health & international development (www.globalbiomedia.co.uk). She predominantly works with NGOs and not-for-profit organisations. Previously she was the senior science editor at TDR, based at the World Health Organization (WHO) in Geneva; prior to this she worked at the Wellcome Trust, UK, leading educational projects on international health topics including trypanosomiasis and trachoma. She has a PhD in immunology and a specialist degree in science communication. She also has several years research and postgraduate teaching experience. She is a member of the HIFA Steering Group and HIFA Social Media Working Group. https://www.hifa.org/support/members/julie-n
[*Note from HIFA moderator (NPW): Thanks Julie. Here is an extract from a Cochrane news item:
'Karen Luyt, Professor in Neonatal Medicine at the University of Bristol... worked alongside clinicians around the world to develop materials to help people in lower-resource settings to implement magnesium sulphate alongside other interventions to help premature babies. In her new editorial in the Cochrane Library, she urges increased global uptake and implementation research in lower-resource settings..." "The trials combined in our review are all from high-income countries, where hospitals are comparatively well set-up to administer magnesium sulphate infusions and fulfil maternal and fetal monitoring requirements,” says Dr Emily Shepherd of the South Australian Health and Medical Research Institute, lead author of the updated Cochrane review. “In low resource settings, this may not always be possible. It would be helpful for future studies to establish the minimum effective dose, and alternative or simpler regimens, particularly intramuscular administration [current administration requires ivi], to aid widespread implementation including across low and middle-income countries."]